Denali expects $30M-$32M Q4 AVLAYAH net product revenue as Sanfilippo BLA filing remains planned for 2027

• Ryan Watts (Co-Founder, President, CEO & Director) framed the quarter around AVLAYAH commercialization and broader platform validation, saying, "This was a defining quarter for Denali" and adding, "AVLAYAH is the first new FDA-approved therapy in nearly 20 years" for Hunter syndrome.

Seeking Alpha's Disclaimer: This article was automatically generated by an AI tool based on content available on the Seeking Alpha website, and has not been curated or reviewed by humans. Due to inherent limitations in using AI-based tools, the accuracy, completeness, or timeliness of such articles cannot be guaranteed. This article is intended for informational purposes only. Seeking Alpha does not take account of your objectives or your financial situation and does not offer any personalized investment advice. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank.